
The Deadly Secrets Behind “Breakthrough” Alzheimer’s Drugs
Regulators approved controversial therapies amid excess deaths, questionable efficacy, and conflicts of interest.
Deep dives into the political corruption and corporate bureaucracy that keeps Americans sick while making executives rich.
Regulators approved controversial therapies amid excess deaths, questionable efficacy, and conflicts of interest.
Alzheimer’s Disease shrinks your brain — why do the new drugs for the condition do the same thing?
Drugmakers say small brain bleeds and swelling caused by the new Alzheimer’s drugs are benign and self-resolving — but are they?
A groundbreaking study finds doctors affiliated with hospitals and private equity firms are charging billions more annually than independent general practitioners.
While proponents claim direct-to-consumer drug ads educate consumers, critics say that mass-market misinformation is costing patients and taxpayers alike.
The Biden administration just delivered a sweetheart deal to its friends at McKinsey, letting the consulting giant off the hook for helping to “turbocharge” disastrous OxyContin sales.
Censorship gets banned, youth score a climate win, nurses win a major union vote, workers’ rights are clear and unmistakable, and small businesses go boom.
“Uber for nurses” is extracting profits and hurting health care, all to solve a problem that doesn’t exist.
Failure to block the insurance giant’s market consolidation, including by a judge with a potential conflict of interest, has led to worse care, higher prices, and a mounting human toll.